Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marc Navre is active.

Publication


Featured researches published by Marc Navre.


Bioorganic & Medicinal Chemistry Letters | 2010

Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides.

Jerome C. Bressi; Andy Jennings; Robert J. Skene; Yiqin Wu; Robert Melkus; Ron de Jong; Shawn O’Connell; Charles E. Grimshaw; Marc Navre; Anthony R. Gangloff

A series of N-(2-amino-5-substituted phenyl)benzamides (3-21) were designed, synthesized and evaluated for their inhibition of HDAC2 and their cytotoxicity in HCT116 cancer cells. Multiple compounds from this series demonstrated time-dependent binding kinetics that is rationalized using a co-complex crystal structure of HDAC2 and N-(4-aminobiphenyl-3-yl)benzamide (6).


Journal of Medicinal Chemistry | 2011

Design and Synthesis of Pyrimidinone and Pyrimidinedione Inhibitors of Dipeptidyl Peptidase IV.

Zhiyuan Zhang; Michael B. Wallace; Jun Feng; Jeffrey A. Stafford; Robert J. Skene; Lihong Shi; Bumsup Lee; Kathleen Aertgeerts; Andy Jennings; Rongda Xu; Daniel B. Kassel; Stephen W. Kaldor; Marc Navre; David R. Webb; Stephen L. Gwaltney

The discovery of two classes of heterocyclic dipeptidyl peptidase IV (DPP-4) inhibitors, pyrimidinones and pyrimidinediones, is described. After a single oral dose, these potent, selective, and noncovalent inhibitors provide sustained reduction of plasma DPP-4 activity and lowering of blood glucose in animal models of diabetes. Compounds 13a, 27b, and 27j were selected for development.


Bioorganic & Medicinal Chemistry Letters | 2010

Benzimidazole and imidazole inhibitors of histone deacetylases: Synthesis and biological activity.

Jerome C. Bressi; Ron de Jong; Yiqin Wu; Andy Jennings; Jason W. Brown; Shawn O’Connell; Leslie W. Tari; Robert J. Skene; Phong H. Vu; Marc Navre; Xiaodong Cao; Anthony R. Gangloff

A series of N-hydroxy-3-[3-(1-substituted-1H-benzoimidazol-2-yl)-phenyl]-acrylamides (5a-5ab) and N-hydroxy-3-[3-(1,4,5-trisubstituted-1H-imidazol-2-yl)-phenyl]-acrylamides (12a-s) were designed, synthesized, and found to be nanomolar inhibitors of human histone deacetylases. Multiple compounds bearing an N1-piperidine demonstrate EC(50)s of 20-100 nM in human A549, HL60, and PC3 cells, in vitro and in vivo hyperacetylation of histones H3 and H4, and induction of p21(waf). Compound 5x displays efficacy in human tumor xenograft models.


Bioorganic & Medicinal Chemistry Letters | 1998

The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases

Jeremy I. Levin; John F. DiJoseph; Loran M. Killar; Michele A. Sharr; Jerauld S. Skotnicki; Dinesh V. Patel; Xiao-Yi Xiao; Lihong Shi; Marc Navre; David A. Campbell

A series of succinyl based mercaptoketones and diastereomeric mercaptoalcohols were prepared and evaluated in vitro as inhibitors of the matrix metalloproteinases collagenase-1 (MMP-1), stromelysin (MMP-3), and gelatinase-B (MMP-9).


Bioorganic & Medicinal Chemistry Letters | 1998

Malonyl α-mercaptoketones and α-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors

David Alan Campbell; Xiao-Yi Xiao; David Harris; Satoru Ida; Reza Mortezaei; Khehyong Ngu; Lihong Shi; David Tien; Yongwen Wang; Marc Navre; Dinesh V. Patel; Michele A. Sharr; John F. DiJoseph; Loran M. Killar; Christina Louise Leone; Jeremy I. Levin; Jerauld S. Skotnicki

Abstract A novel series of matrix metalloproteinase (MMP) inhibitors is described. Incorporation of a terminal α-mercaptoketone or α-mercaptoalcohol in the zinc binding domain of a series of inhibitors led to compounds exhibiting low nanomolar activity against collagenase-1 (MMP-1), stromelysin (MMP-3), and gelatinase-B (MMP-9).


Journal of Medicinal Chemistry | 2018

Design of Gut-Restricted Thiazolidine Agonists of G Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5)

Tao Chen; Nicholas Reich; Noah Bell; Patricia D. Finn; David Rodríguez; Jill Kohler; Kenji Kozuka; Limin He; Andrew Spencer; Dominique Charmot; Marc Navre; Christopher Carreras; Samantha Koo-McCoy; Jocelyn Tabora; Jeremy S. Caldwell; Jeffrey W. Jacobs; Jason G. Lewis

Bile acid signaling and metabolism in the gastrointestinal tract have wide-ranging influences on systemic disease. G protein-coupled bile acid receptor 1 (GPBAR1, TGR5) is one of the major effectors in bile acid sensing, with demonstrated influence on metabolic, inflammatory, and proliferative processes. The pharmacologic utility of TGR5 agonists has been limited by systemic target-related effects such as excessive gallbladder filling and blockade of gallbladder emptying. Gut-restricted TGR5 agonists, however, have the potential to avoid these side effects and consequently be developed into drugs with acceptable safety profiles. We describe the discovery and optimization of a series of gut-restricted TGR5 agonists that elicit a potent response in mice, with minimal gallbladder-related effects. The series includes 12 (TGR5 EC50: human, 143 nM; mouse, 1.2 nM), a compound with minimal systemic availability that may have therapeutic value to patients with type 2 diabetes mellitus, nonalcoholic steatohepatitis, or inflammatory bowel disease.


Structure | 2004

Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases

John R. Somoza; Robert J. Skene; Bradley A. Katz; Clifford D. Mol; Joseph D. Ho; Andy Jennings; Christine Luong; Andrew S. Arvai; Joseph J. Buggy; Ellen Chi; Jie Tang; Bi-Ching Sang; Erik Verner; Robert Wynands; Ellen M. Leahy; Douglas R. Dougan; Gyorgy Snell; Marc Navre; Mark W. Knuth; Ronald V. Swanson; Duncan E. McRee; Leslie W. Tari


Journal of Medicinal Chemistry | 2007

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.

Jun Feng; Zhiyuan Zhang; Michael B. Wallace; Jeffrey A. Stafford; Stephen W. Kaldor; Daniel B. Kassel; Marc Navre; Lihong Shi; Robert J. Skene; Tomoko Asakawa; Koji Takeuchi; Rongda Xu; David R. Webb; Stephen L. Gwaltney


Biochemical and Biophysical Research Communications | 2006

Characterization of the two catalytic domains in histone deacetylase 6.

Hua Zou; Yiqin Wu; Marc Navre; Bi-Ching Sang


Journal of Medicinal Chemistry | 1999

Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.

Anna Katrin Szardenings; Valery V. Antonenko; David Alan Campbell; Nuria DeFrancisco; Satoru Ida; Lihong Shi; Nikolai Sharkov; David Tien; Yongwen Wang; Marc Navre

Collaboration


Dive into the Marc Navre's collaboration.

Top Co-Authors

Avatar

Lihong Shi

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Robert J. Skene

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Andy Jennings

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Yiqin Wu

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Bi-Ching Sang

Takeda Pharmaceutical Company

View shared research outputs
Researchain Logo
Decentralizing Knowledge